Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

PRINCETON, N.J., Sept. 3 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Global Investor Healthcare Conference. Dr. Schaber is scheduled to present at 4:55 PM on Thursday, September 10, 2009 in the Spellman Salon of the New York Palace Hotel, New York. The presentation will be webcast live and may be accessed by visiting http://www.wsw.com/webcast/rrshq15/dorb.ob.

Dr. Schaber will provide updates on DOR's pipeline, including its lead product candidate orBec(R) which is soon to begin a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

A replay of Dr. Schaber's webcast will be available on DOR BioPharma's new website (www.dorbiopharma.com) for approximately 30 days following the presentation.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clin
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 Investor-Edge ... (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... on these five companies can be accessed at: ... October 23, 2014, ended on a positive note as ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report ... Americas with analysis and forecast of revenue. , ... Refrigerants Market report, to get an idea of ... glimpse of the segmentation in the Americas inorganic ... and figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
... Switzerland, August 19 Arpida Ltd,(SIX: ARPN) announced today its financial results ... Key events 2009 to date, - Regulatory setback for ... under review, - Company restructuring completed, , ... June 2009 , CFO Harry Welten, MBA, commented: ...
... , WESTON, Fla., Aug. 19 In keeping with ... of families, America n Scientific Resources ... obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell ... and the Disintegrator Plus(TM). , , All ...
... , , LONDON, Aug. 19 ... the introduction of improved drugs to treat the disease. As healthcare ... companies conducting research on diabetes vaccines. If they succeed, the entire ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 3Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 2Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 3
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... West Indian tarantula has been shown to cause pain ... sense high temperatures and the hot, spicy ingredient in ... demonstrate that some plants and animals have evolved the ... by activating a specific receptor on sensory nerves. The ...
... gardener knows--different plant species mature at different times. ... this phenomenon "complementarity." It allows many species to ... period when species compete for limited resources. Now, ... Sept. 4 in the Proceedings of the National ...
... the limb regrows. What is more, a newt can also ... Planck Institute for Heart and Lung Research in Bad Nauheim ... impressive ability to regenerate and have discovered the remarkable plasticity ... do not have this ability, the findings could contribute to ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Global changes alter the timing of plant growth, scientists say 2Global changes alter the timing of plant growth, scientists say 3Newts which regrow their hearts 2
... fluorescein-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
... lower cost and reduced space requirements ... reference standard DNA analysis technology affordable ... with any of SEQUENOM's applications and ... (iPLEXTM Gold) , Gene Expression Analysis ...
... Bruker Daltonics and Bruker BioSpins Metabolic ... metabolism studies, and analysis of complex ... system, an optional Avance NMR spectrometer ... evaluation and statistical analysis for applications ...
Biology Products: